News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Specialty Vaccine Company PaxVax, Inc. Appoints Mark Meltz Executive Vice President And Chief Legal Officer



9/3/2014 10:26:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice President and Chief Legal Officer. In this role, Mr. Meltz will oversee all legal, intellectual property, business development, government affairs, compliance and corporate governance matters for the company.

Mr. Meltz joins PaxVax from Biogen Idec, where he was Associate General Counsel. In this role, he was the lead U.S. commercial lawyer for Tecfidera®, an oral multiple sclerosis therapy with sales of more than $1 billion in the U.S. since its launch in 2013. Prior, he was Head of Legal for North America at Novartis Vaccines and Diagnostics, where he had general counsel responsibilities for the U.S. and Canadian vaccine businesses. Previously, he served in a similar capacity for the Latin American region. Mr. Meltz also served as Counsel at global law firm Bingham McCutchen, where his work focused on mergers and acquisitions, venture capital financing, securities regulation and general corporate matters. Mr. Meltz holds a B.A. from Yale University and a J.D. from Boston College Law School.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES